Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...

The rise in GLP-1 drugs is undeniable. Morgan Stanley projects that by 2035, 24 million Americans, or 7% of the population, ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Dublin, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The "Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control, and adding savory flavors are ways that ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...

Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...